Compare STTK & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | ASLE |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 296.8M |
| IPO Year | 2020 | 2018 |
| Metric | STTK | ASLE |
|---|---|---|
| Price | $6.18 | $6.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $7.60 | $7.00 |
| AVG Volume (30 Days) | ★ 617.5K | 258.1K |
| Earning Date | 03-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 63.64 |
| EPS | N/A | ★ 0.18 |
| Revenue | $1,000,000.00 | ★ $335,286,000.00 |
| Revenue This Year | N/A | $24.23 |
| Revenue Next Year | N/A | $23.67 |
| P/E Ratio | ★ N/A | $34.86 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $5.56 |
| 52 Week High | $6.27 | $9.08 |
| Indicator | STTK | ASLE |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 26.74 |
| Support Level | $1.85 | $5.69 |
| Resistance Level | N/A | $6.56 |
| Average True Range (ATR) | 0.42 | 0.24 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 93.80 | 7.98 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.